Details, Fiction and QST4
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major demo objectives ended up to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis su